---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-057501"
form_type: "8-K"
ticker: "JAGX"
cik: "0001585608"
company_name: "Jaguar Health, Inc."
filed_at: "2023-05-09T23:59:59+00:00"
generated_at: "2026-06-15T09:09:17.324387+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Jaguar Health completes enrollment in pivotal Phase 3 OnTarget trial; raises $1.86M in PIPE financing

## Summary
- Enrolled target 256 patients in Phase 3 OnTarget trial for crofelemer to prevent cancer therapy-related diarrhea; top-line results expected early Q4 2023.
- Private placement raises ~$1.86M via 137 Series G convertible preferred shares (convertible at $0.5423) and 6,850,000 warrants at $0.48 exercise price.
- Warrants exercisable from later of Jan 1, 2024 or stockholder approval, for 5 years; no anti-dilution or variable pricing.
- Standstill agreement with Iliad, Uptown, Streeterville suspends royalty payments for up to 6 months; they receive warrants for ~3.82M shares.
- Company agrees not to issue additional equity securities before Oct 22, 2023, except with PIPE investor consent.

## SEC filing metadata
- accession: 0001104659-23-057501
- form_type: 8-K
- ticker: JAGX
- cik: 0001585608
- company_name: Jaguar Health, Inc.
- filed_at: 2023-05-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 5.03, 2.03, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1585608/000110465923057501/0001104659-23-057501-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1585608/000110465923057501/tm2315061d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-057501
- JSON: https://secwatch.observer/filing/0001104659-23-057501.json
- Plain text: https://secwatch.observer/filing/0001104659-23-057501.txt

## Key facts
- Governance Changes
  Jaguar Health, Inc.: Created Series G Preferred Stock via Certificate of Designation, establishing its preferences, rights, and limitations.
  - Change: charter amendment
  source text: Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. Series G Certificate of Designation As disclosed under Items 1.01 and 3.02 above, in connection with the Private Placement, the Company agreed to issue the Series G Preferred Stock to the Purchasers. The preferences, rights, limitations and other matters relating to the Series G Preferred Stock are set forth in the Certificate of Designation.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1585608/000110465923057501/0001104659-23-057501-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.